Table 1.
Sonodynamic therapy of cell cultures and suspensions
Cancer cell culture/suspension |
Sonosensitizer | Insonation parameters | Reference | |
---|---|---|---|---|
MHz | W.cm−2 | |||
(i) murine sarcoma 180 | hematoporphyrin | 1.92 | 1.27-3.18 | Yumita et al.1989 |
II | 1.9 | 1.8 | Umemura et al 1990 | |
II | 1.75 | 1.4 | Tang et al 2008[a] | |
II | 1.8 | 2.1 | Tang et al 2008[c] | |
II | 1.6 | 1.0-6.0 | Wang et al 2008[a] | |
pheobromide-a | 1.92 | 4.5 | Umemura et al 1996[b] | |
ATX-S10 | 1.92 | 4.5 | Yumita et al 2000[a] | |
photofrin II | 1.93 | 5.9 | Yumita et al 2000[c] | |
protoporphyrin IX | 1.0 | 5.0 | Umemura et al 1996[a] | |
II | 2.2 | 1.0-7.0 | Liu et al 2006[b] | |
II | 2.2 | 3.0 | Wang et al 2008[c] | |
II | 2.2 | 3.0 | Wang et al 2008[b] | |
II | 1.1 | 0.64-2.1 | Wang et al 2010 | |
rose Bengal derivative | 1.92 | 2.0-8.0 | Sugita et al 2010 | |
DCPH-P-Na(I) | 2.0 | 5.9 | Yumita et al 2010 | |
NPe6 | 1.92 | 4.5 | Yumita et al 2011 | |
polyhydroxy fullerenes | 1.92 | 4.5 | Yumita et al 2013 | |
(ii) hepatic | hematoporphyrin | 1.92 | 1.27-3.18 | Yumita et al 1989 |
II | 1.43 | 1.0-4.0 | Liu et al 2008[b] | |
titanium nanoparticles | 1.0 | 0.1 | Ninomiya et al 2012 | |
II | 0.5,1.0 | 0.8, 0.4 | Ninomiya et al 2014 | |
hypocrellin-B | 1.7 | 0.46 | Wang et al 2012[a] | |
(iii) nasopharyngeal | curcumin | 1.7 | 0.46 | Wang et al 2011[b] |
II | 1.7 | 0.46 | Wang et al 2011[c] | |
II | 1.7 | 0.46 | Wang et al 2012[b] | |
(iv) glioma | ZnPcS2P2 | 1.0 | 0.5 | Chen et al 2012[b] |
HMME | 1.0 | 0.5 | Li et al 2013 | |
photofrin | 1.0 | 0.5 | Xu et al 2012 | |
II | 1.0 | 0.5 | Xu et al 2013 | |
titanium nanoparticles | 1.0 | 1.0 | Yamaguchi et al 2011[b] | |
(v) human breast | protoporphyrin IX | 1.1 | 1.0 | Li et al 2012[a] |
chlorin e6 | 1.0 | 0.36, 0.72 | Wang et al 2013[a] | |
chlorin e6 + adriamycin | 1.0 | 0.5-2.0 | Gao et al 2010 | |
(vi) ovarian | cisplantin | 1.0 | 2.0 | Bernard et al 2011 |
methylene blue | 1.7 | 0.46 | Xiang et al 2011 | |
(vii) other | ||||
acute myeloid leukemia | chlorine e6 | 1.1 | 1.0 | Su et al 2013[b] |
cholangiocarcinoma | hematoporphyrin | |||
+ doxorubicin | 1.2 | 0.5-2.0 | Liang et al 2013 | |
Ehrlich ascites | protoporphyrin IX | 1.34 | 1.0-5.0 | Zhao et al 2009 |
gastric | antibody/porphyrin | 1.0 | 1.0 | Abe et al 2002 |
human leukemia | protoporphyrin IX | 1.1 | 1.0 | Su et al 2014 |
human melanoma | cisplatin | 1.0 | 1.0 | Bernard et al 2012 |
histiocytic lymphoma | hematoporphyrin | 1.1 | 1.0 | Su et al 2013[a] |
murine leukemia | protoporphyrin IX | 1.1 | 0.64-2.1 | Wang et al 2013[b] |
murine mammary | chlorine e6 | 1.0 | 0.36, 0.72 | Li et al 2013 |
tongue | 5-aminolevulinic acid | 1.0 | 0.6, 0.8 | Lv et al 2012 |
multiple cell lines | porphyrin derivative | 1.0 | 1.0 | Tsuru et al 2012 |
porphyrin derivative | 1.0 | 0.5-2.0 | Hachimine et al 2007 | |
(viii) non-neoplastic (endothelial cells) |
5-aminolevulinic acid | 1.0 | 1.0 | Gao et al 2013 |
Key: ATX-S10 = 4-formyloximethylidene-3-hydroxy-2-vinyl-deuterio-porphynyl(IX)-6,7-diaspartic acid; DCPH-P-Na(I) = 13,17-bis(1-carboxyethyl)-8-[2-(2,4-dichlorophenyl-hydrazono)ethylidene]-3-ethenyl-7-hydroxy-2,7,12,18-tetramethylchlorin; Pe6 = mono-l-aspartyl chlorin e6; HMME = hematoporphyrin monomethyl ether